Search

file (10) (1)

OBI Information

News

HOMEWhat’s NewNews

2025.Jun.10

Corporate

OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit

2025.Jun.06

Corporate

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

2025.May.01

Corporate

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

2025.Apr.29

Corporate

OBI Pharma Unveils New ThiOBI® and HYPrOBI™ Platforms
Showcasing Strong ADC Development Capabilities and Captivating Attention at AACR

2025.Apr.23

Corporate

OBI-822 Completes Second Interim Analysis of Phase III Trial
OBI Announces Trial Termination, Refocuses Resources on ADC Development

2025.Apr.23

Corporate

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs),
GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science.

2025.Mar.28

Corporate

GlycOBI® Advances Bispecific and Dual Payload ADC Development
OBI Demonstrates Innovations at the Novel Conjugates Summit in Boston

2025.Mar.26

Corporate

Award & Certification​

OBI Wins " Most Promising Immunotherapy Pipeline" Award
Showcasing TROP2 ADC Research at Biologics World Taiwan

2025.Mar.18

Corporate

New Chairman of OBIGEN Pharma: OBI Pharma CEO Heidi Wang Takes Over

2025.Mar.12

Corporate

Award & Certification​

OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation

Announcements

Latest announcements

Events

Latest events